Loading...
Loading...
PRTG| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 13.0K |
| Gross Profit | -13.0K |
| Operating Expense | 3,247.0K |
| Operating I/L | -3,260.0K |
| Other Income/Expense | -21,665.0K |
| Interest Income | 60.0K |
| Pretax | -24,905.0K |
| Income Tax Expense | 1.0K |
| Net Income/Loss | -24,889.0K |
Portage Biotech Inc. and its subsidiaries specialize in researching and developing pharmaceutical and biotechnology products. Their product portfolio includes a range of innovative treatments such as IMM60, IMM65, INT230-6, STING, CellPorter, PPL-003, and SBI-101, targeting various medical conditions including cancer, ophthalmic disorders, and acute vital organ injuries. The company also focuses on nanolipogel technology for immune-oncology, antibodies for malignancies, and antibodies related to inflammatory tumor and immune cell microenvironments. Additionally, they are developing the FOXO4-P53 modulator and C-RAF inhibitor. These products form the core of their revenue generation and business operations.
